Home › NCT06531863

Curcumin and EGCG Supplementation to Improve Serum BDNF and Mood Disturbance

A Randomized Controlled Trial to Determine the Effects of Curcumin and Epigallocatechin Gallate Supplementation on Serum Brain Derived Neurotrophic Factor and Mood Disturbance in Adults

Who can join

Ages 18 to 50 · All sexes · Healthy volunteers welcome

Inclusion Criteria:

* Adults age 18-50
* Depression subscale score of \>9/21 on the DASS-21
* No change in medications or supplements over the past 3 months
* Can read and speak English

Exclusion Criteria:

* Currently consume curcumin or green tea daily
* Currently, pregnant, nursing, or trying to become pregnant
* Currently diagnosed with a perimenopausal disorder

About the study

The goal of this randomized placebo controlled trial is to examine mood disturbance and serum brain derived neurotrophic factor (BDNF) in people (age 18-50) with DASS-21 subscale scores \>9. The main questions it aims to answer are:

Does curcumin and EGCG supplementation improve mood disturbance symptomology? Does curcumin and EGCG supplementation increase serum BDNF? Researchers will compare intervention versus placebo.

Participants will consume an 8-week supplement of both:

* 1,330mg/day curcumin * 350mg/day epigallocatechin gallate (EGCG)

What is being tested

• Curcumin (dietary supplement)
• Epigallocatechin Gallate (dietary supplement)
• Placebo (other)

Sponsor: Auburn University · Participants: 64 · Started: Sep 30, 2024

Contact the study team

• Aidan Cavanah, MSc · Phone: 2057893258

Official record on ClinicalTrials.gov — NCT06531863

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.